Kornimate/medical-research-clean huggingface dataset:
managing fear of cancer progression metacognition-based vs supportive-expressive based approaches

Conditions: Advanced or Metastatic Cancer; Fear of Cancer Progression; Metacognition-based Intervention; Supportive-expressive Based Intervention; Psychooncology

Summary: the present study aims to conduct a randomized controlled trial to assess the effect of calm intervention and conquerfear intervention on fear of cancer progression among chinese patients diagnosed with advanced cancer.

a randomized controlled trial will be conducted to assess the effect of calm intervention and conquerfear intervention on fear of cancer progression among chinese patients diagnosed with advanced cancer. the aims are to test: 1. the direct effect of calm intervention or conquerfear intervention on fear of cancer progression, and 2. the indirect effect of conquerfear intervention on fear of cancer progression through its effect on maladaptive metacognition. primary hypothesis: 1. patients receiving calm intervention or conquerfear intervention, compared to those receiving a basic cancer care intervention will show a reduction in fear of cancer progression. 2. both calm intervention and conquerfear intervention will be equally effective in reducing fear of cancer progression. 3. given conquerfear intervention aims to modify unhelpful metacognitive beliefs, there will be an indirect effect of conquerfear intervention on fear of cancer progression through its effect on maladaptive metacognition.

Eligibility criteria:
inclusion criteria: * cantonese- or mandarin-speaking chinese patients recently diagnosed with advanced or metastatic (i.e. stage iii or iv) cancer * are the age of 18 years or above exclusion criteria: * patients with major communication difficulties * are being unwilling or unable to commit 6 psychotherapy sessions
exploring life experience and lifestyle intervention program among patients with chronic kidney disease: a longitudinal study

Conditions: Chronic Kidney Disease

Summary: the lifestyle consulting program through one year follow-up could effective increase the scores of health responsibility and nutrition according to the past three-year study. behavior change is a dynamic and complex process. using a long-term follow up approach will be able to understand the trajectory of behavior change. the purpose of this study is to explore life experience and lifestyle intervention program for patients with chronic kidney disease using mixed methods with a longitudinal approach. the first year of this study will include a qualitative study with in depth interview of the subjects who attend previous study in the research team and have the scores of health promoting lifestyle among the highest 27% and lowest 27%. the life experience will be explored. the quantitative study will be an experimental design. qualified subjects will be randomly assigned to intervention or control group. the intervention protocol is based on trans-theoretical model. each subject will be followed every six months. the second and third year of studies will continue to use the qualitative and quantitative approach to understand the life experience and meaning among patients with chronic kidney diseases. the trajectory of life experience and life style changes will be explored. the method may strengthen the effectiveness of lifestyle program and may provide comprehensive understanding of the trajectory of behavior changes among patient with chronic kidney disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of early stages of chronic kidney disease (gfr≧30ml/min/1.73㎡) * must be able to commmunicate in chinese or taiwanese * muse be voluntarily to attend * patient who does not exercise regularly * patient whose blood pressure higher than 140/90 mmhg * patient who is overweight or bmi\>25kg/㎡ exclusion criteria: * patient who limited to exercise

Keywords: life experience life style health behavior mixed method
the evaluation of banana flower stamens extract on prevention of benign prostatic hyperplasia in adults

Conditions: Benign Prostatic Hyperplasia (BPH)

Summary: to assess the evaluation of banana flower stamens extract on prevention of benign prostatic hyperplasia in adults

this is a double-blind and randomized study. subjects are informed to consume the samples every day for 2 months. the clinical diagnosis item of benign prostatic hyperplasia (bph) is evaluated by the doctor. the questionnaires are collected at every visit of the trial.

Eligibility criteria:
inclusion criteria: 1. male aged 40-80 years old 2. 7 ≤ ipss score \<19 3. the subject did not take α-blocker or anticholinergic agents in the last 8 weeks. the subject did not take 5α-reductase inhibitor or androgen suppression agents in the last 16 weeks (depending on medical history). 4. the subject isn't diagnosed with cancer 5. the subject is able to read and finish the information on the questionnaire. 6. the subject must read and sign the informed consent form after the study has been fully explained. exclusion criteria: 1. the subject has a history of epilepsy or convulsions, liver and kidney disease, cancer, endocrine disease, mental illness, alcohol or drug abuse, and other major organic diseases (depending on medical history). 2. the lower urinary tract urination symptoms of the subject are not related to prostatic hypertrophy (depending on medical history). 3. residual urine volume \> 250 ml (depending on medical history) 4. subjects have had pelvic radiation therapy or pelvic surgery (including prostate or bladder surgery, but those who only have had a prostate slice can participate in the trial). 5. subjects have taken sexual hormone preparations including lhrh agonists, anti-androgens, feminine, or penta-reductase inhibitors (proscar and avodart) 16 weeks prior to the trial. 6. subjects have participated in other clinical trials 12 weeks prior to the trial.
effects of prophylactic desmopressin on blood coagulation parameters in heart valve surgery

Conditions: C.Surgical Procedure; Cardiac; Blood Coagulation Disorders

Summary: the purpose of this study is evaluate the effect of prophylactic desmopressin on blood coagulation parameters and postoperative bleeding in patients undergoing valve cardiac surgery with cardiopulmonary bypass.

patients with important valve disorders may evaluate with coagulopathy induced by mechanical effects (valvular stenosis or valvular insufficiency). furthermore, frequently is required prophylactic use of antiplatelet drugs due to myocardial remodeling and antiarrhythmic conditions that may be associated. patients with severe aortic stenosis may also acquired von willebrand disease type 2a due to proteolysis of vonwillebrand factor. despite of this, the treatment of valve disorders often requires cardiac surgery with cardiopulmonary bypass. on average 50 to 60% of patients undergoing cardiac surgery receive blood tranfusions. blood cell transfusion is an independent risk factor for increased morbidity and mortality in critically ill patients. the use of desmopressin seems beneficial only in patients with congenital or acquired platelet dysfunction. in general population, such use is not validated due to inconclusive results of researches.

Eligibility criteria:
inclusion criteria: * valve cardiac surgery with cardiopulmonary bypass. * written informed consent exclusion criteria: * reoperative valve surgery * hematocrit \< 35% * ventricular dysfunction (ef \< 40%) * infection * body mass index \> 35 * renal impairment (creatinin \> 2mg/dl) * antiplatelet administration within 10 days preceding study surgery * participation in another interventional clinical study within 30 days * known or suspected hypersensitivity to the desmopressin * coagulopathy (inr \> 1.5)

Keywords: bleeding valve cardiac surgery desmopressin
study examining the promus element everolimus-eluting stent in multi-center coronary intervention of complex arterial lesion subsets

Conditions: Coronary Artery Disease

Summary: randomized trials have demonstrated an excellent safety and efficacy profile for the chromium everolimus-eluting stent. the platinum chromium everolimus-eluting sten (ptcr-ees) uses the identical antiproliferative agent and polymer but with a novel platinum chromium scaffold designed for enhanced deliverability, vessel conformability, side-branch access, radiopacity, radial strength, and fracture resistance. however, the efficacy of the ptcr-ees for complex coronary artery diseases subsets such as chronic total occlusion, bifurcation lesion, left main trunk disease, and small vessel diseases is still unknown.


Eligibility criteria:
inclusion criteria: 1. a patient with ischemic heart disease including stable angina pectoris and acute coronary syndrome 2. male or non-pregnant female 3. key lesion inclusion criteria as follows 1. multi-vessel diseases 2. long lesion (lesion length \>30mm by visual estimation) 3. small vessel disease (reference diameter \<2.5mm by visual estimation) 4. bifurcation lesion 5. ostial lesion 6. calcified lesion 7. protected or non-protected left main trunk disease 8. chronic total occlusion 9. in stent restenosis of bare metal stent or everolimus-eluting stent exclusion criteria: 1. hypersensitivity to cobalt chromium, everolimus, heparin, aspirin, ticlopidine, clopidogrel or x-ray contrast media. 2. serum creatinine level \>3.0 mg/dl 3. other concomitant disease or medical condition that could impact patient/procedural outcomes, such as history of bleeding diathesis or cancer within 5 years.

Keywords: chronic total occlusion bifurcation lesion left main trunk lesion small vessel disease multi vessel disease
study of indomethacin capsules to treat pain following bunionectomy

Conditions: Other Acute Postoperative Pain

Summary: the purpose of this study is to determine whether indomethacin \[test\] capsules are safe and effective for the treatment of postoperative bunionectomy pain.


Eligibility criteria:
inclusion criteria: * patient is male or female between 18 and 65 years of age * for women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control * has undergone primary, unilateral, first metatarsal bunionectomy with no additional collateral procedures * patient must be willing to stay at the study site ≥ 72 hours exclusion criteria: * patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs * patient has a current disease or history of a disease that will impact the study or the patient's well-being * patient has used or intends to use any of the medications that are prohibited by the protocol * patient has a history of drug or alcohol abuse or dependence, or patient has a positive urine drug screen or alcohol breathalyzer test * patient has taken another investigational drug within 30 days prior to screening
early and intermittent antiretroviral therapy in naive hiv infected adults

Conditions: HIV Infections

Summary: the primary objective of the trial is to assess the ability of an early and intermittent antiretroviral therapy in maintaining an immunological stability in antiretroviral naive hiv infected adults, to offer a potential alternative strategy to differed and continuous antiretroviral treatment.this is a 2-year phase ii, open-label, multicentric "proof of concept" trial. the patients included are treated following a pulse-therapy scheme, i.e. 6-month periods with once daily boosted-pi based therapy in alternance with 6-month periods without antiretroviral therapy. the preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir.the patients are closely followed to assess the efficacy and the tolerance of the strategy, with clinical, biochemical, immunological, virological and pharmacokinetic evaluations.


Eligibility criteria:
inclusion criteria: * adult confirmed hiv-1 infection * no previous treatment with antiretroviral drugs or interleukin-2 * cd4 count ≥ 500/mm3 * no active opportunistic infection * written informed consent exclusion criteria: * non barrier contraception in women of child bearing potential, pregnant or breastfeeding woman, pregnancy project within the next 2 years * hiv-2 infection (with or without hiv-1), recent hiv primary infection, resistance to trial drugs at study entry, ag hbs+, hcv requiring specific therapy * previous history of cerebrovascular accident or coronary heart disease, splenectomy * previous cd4 count \< 400/mm3 * cd4 percentage \< 15% * hemoglobin \ 3 uln

Keywords: antiretroviral therapy structured treatment interruptions treatment naive
comparative study of blood loss in total laparoscopic hysterectomy by ligation the uterine arteries in different techniques.

Conditions: Gynecologic Disease

Summary: following caesarean section, hysterectomy is the second most common major gynecological surgery, with approximately 600,000 procedures performed annually in the usa. since reich et al. first reported a total laparoscopic hysterectomy (tlh) in 1989, numerous studies have confirmed its feasibility and reproducibility. evidence increasingly supports tlh over vaginal hysterectomy (vh) and total abdominal hysterectomy (tah) for benign gynecological conditions. the development and rapid advancement of laparoscopic instruments and techniques have enabled the safe and successful completion of complex procedures using minimally invasive approaches. women with a higher bmi or requiring complex surgeries benefit from reduced postoperative complications with laparoscopic operations.


Eligibility criteria:
inclusion criteria: * patients aged between 35-60 years patients presented with menometrorrhagia unresponsive to medical treatment, and uterine pathology such as adenomyosis or multiple fibroids. exclusion criteria: * patients were excluded if they had: medical conditions preventing pneumo-peritoneum * patients with medical conditions hindering proper ventilation during general anesthesia. * patients diagnosed with endometrial carcinoma and patients with uterine size larger than 24 weeks were excluded. * patients with excessive adhesions precluding access to the uterine arteries were not enrolled in the study.
evaluation of the right use of inhaled therapeutics

Conditions: COPD Asthma

Summary: asthma and copd have a significant impact on public health, affecting about 8 million people in france and generating health care costs of 5.5 billion euros, almost 50% of which are dedicated to long-term treatments are essentially inhaled therapies. the good control of the disease depends on the patient's compliance, but also on the proper use of the devices used for the administration of inhaled drugs under penalty of the degradation of the control of the disease with major medical and medico-economic consequences. thus, education of these patients in the use of devices must be an integral part of medical care. it comes up against the complexity of the therapeutic arsenal on the one hand and on the other hand with its time-consuming nature: this makes it incompatible with a realization in consultation. the "argos" process is a telemonitoring project for the support of therapeutic education, consisting in setting up a concrete and real-time relay between prescribers and patients for the education of inhaled therapeutics. its objective is to provide the answer to what is currently an "unmet need" in the management of asthma and copd, with the prospect of a positive impact on the observance of these treatments and by consequently their clinical and economic efficiency.


Eligibility criteria:
inclusion criteria: * patient followed in pneumology for asthma or copd with a prescription for long-term inhaled therapies and a home health provider (who monitors either home oxygen and / or respiratory equipment) * the patient must have a means of telephone communication in order to be able to be contacted by a provider, an h2ad permanence or a doctor * patient having given his agreement after having been informed in writing of the purpose and the data collected during this study * age ≥ 18 years * beneficiary of a social security scheme exclusion criteria: * refusal of the patient * patient not understanding french * absence of home health provider * absence of means of telephone communication

Keywords: copd asthma inhaled therapeutics
pulmonary outcomes of bronchopulmonary dysplasia in young adulthood

Conditions: Premature Birth; Obstructive Lung Disease; Bronchopulmonary Dysplasia

Summary: preterm birth alters the normal sequence of lung development with lasting respiratory consequences. it is still unclear whether observed respiratory morbidities in preterm born individuals reflect sequelae from a non-progressive lung disease that occurred early in life or result from ongoing active disease that, if left undiagnosed and untreated, could increase the risk of a copd-like phenotype. we propose to examine micro-structural abnormalities of the lung using innovative non-invasive imaging technologies in relation to pulmonary function and markers of inflammation and oxidative stress in young adults born preterm.


Eligibility criteria:
inclusion criteria: * 20-29 years old * for the pre-term subject: \<29 weeks gestational age, with or without bpd * for the matched term control: ≥37 weeks gestational age with birth weight appropriate for gestational age i.e. between the 10th and 90th percentile * subject understands the study procedures and is willing to participate in the study as indicated by the signature on the informed consent * subject is judged to be in otherwise stable health on the basis of medical history * subject is able to perform reproducible pulmonary function testing (i.e., the 3 best acceptable spirograms have fev1 values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater) exclusion criteria: * patient is, in the opinion of the investigator, mentally or legally incapacitated, preventing informed consent from being obtained, or cannot read or understand the written material * patient is unable to perform spirometry or plethysmography maneuvers * subject has an implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants)(at the discretion of the mri technologist/3t manager) * in the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the mri, such as severe claustrophobia

Keywords: thoracic magnetic resonance imaging pulmonary function test
the efficacy and safety of ache inhibitor donepezil as adjunctive treatment to mood stabilizers in acute mania

Conditions: Bipolar Disorder; Mania

Summary: there is a high rate of partial response to standard thymoleptic medication. in this study the investigators want to evaluate the safety and efficacy of donepezil as adjunctive treatment to mood stabilizers in bipolar disorder with acute mania. the investigators hypotheses were that there would be greater mean reduction in manic symptoms with donepezil augmentation of lithium compared with placebo.

bipolar disorder is a chronic mental illness that affects 1-2% of the general population. lithium and valproate are effective for treatment of acute mania for many patients. however up to half of patients do not respond adequately to currently approved treatments in the acute phase of mania. more effective treatment for mania are need. imbalance in cholinergic and adrenergic tone has long been postulated in the pathophysiology of bipolar disorder. in the pathophysiology of mania,relative cholinergic hypoactivity was being implicated. donepezil is a centrally acting reversible acetylcholinesterase inhibitor. it is approved for the treatment of alzheimer's disease. in an open case series with standardized ratings, addition of donepezil 5-10 mg/day to ongoing mood-stabilizer treatment was associated with marked improvement in treatment-resistant mania. we want to conduct a 4-week randomized, double-blind, placebo-controlled trial of donepezil as augmentation of lithium in patients with acute manic episode to evaluate the safety and efficacy of donepezil as adjunctive treatment to mood stabilizers in bipolar disorder with acute mania.

Eligibility criteria:
inclusion criteria: 1. patients have dsm-iv diagnosis of bipolar disorder with acute manic episode who are admitted as inpatient 2. young mania rating scale (ymrs) total score \>20 (based on mean scores of two ratings after admission) 3. physical examination, laboratory results (eg.ekg) from screening visit normal, or abnormal clinically insignificant exclusion criteria: 1. having history of allergy to donepezil or lithium. 2. having active suicide or homicide attempt or intent 3. having severe medical conditions or taking multiple medications for medical conditions 4. investigational drug treatment within past 30 days 5. having a drug screen positive for any drug of abuse at screening 6. self-report of active substance abuse in the past 2 weeks or substance dependence in the past 2 months 7. diagnosis of schizophrenia, dementia, delirium, seizure disorder, obsessive compulsive disorder, or unstable medical condition 8. administration of any investigational drug within 30 days of screening 9. pregnancy or lactation 10. asthma requiring chronic medication treatment or ongoing use of anticholinergic medications or cholinomimetics 11. other factors that investigator consider not suitable for the study

Keywords: acetylcholinesterase inhibitor donepezil bipolar disorder mania lithium